CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine
December 26, 2024
Source: drugdu
29
CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine
Finance China News, December 20 – CanSino (688185/06185) released a voluntary disclosure announcing the official launch of Phase II/III clinical trials for its adsorbed acellular DTaP (Diphtheria, Tetanus, and Pertussis) combined vaccine (for individuals aged 6 and older), having completed enrollment of the first subject in Phase II. This vaccine aims to provide booster immunization for adolescents and adults, filling a gap in the domestic market.
Currently, the vaccine has completed Phase I clinical trials, with results indicating that its immunogenicity meets expectations and that it is safe. The ongoing Phase II/III clinical trials will further assess the vaccine's immunogenicity and safety. The company will strictly advance the clinical trials in accordance with national drug registration regulations, despite the complexity and uncertainty inherent in the vaccine development process.
In the first three quarters of 2024, CanSino achieved revenue of 567 million yuan and a net profit attributable to the parent company of -222 million yuan.
https://finance.eastmoney.com/a/202412203274626914.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Cluster development of Changchun’s pharmaceutical and health industry December 26, 2024
- Billions of yuan! Cardiovascular innovative equipment company completes Series C financing December 26, 2024
- Lianying 5T MR wins bid again, will domestic ultra-high field magnetic resonance imaging explode? December 26, 2024
- Oncology drug competition has reached a new height December 26, 2024
- Planning a Share Swap to Absorb and Merge with Shanghai Raas December 26, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
